Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution
- 72 Downloads
Correction to: J ImmunoTher Cancer
Following publication of the original article , the authors have reported that the following sentence “While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells.”
should be replaced with
“Ipilimumab and AGEN1884 are IgG1 class antibodies. AGEN1884 data show CTLA-4 inhibition and activity against T regulatory cells (reference 8).”
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.